STSS vs. NDRA, HSDT, AVGR, NAYA, NVIVQ, AFIB, DYNT, BJDX, CUTR, and SONX
Should you be buying Sharps Technology stock or one of its competitors? The main competitors of Sharps Technology include ENDRA Life Sciences (NDRA), Helius Medical Technologies (HSDT), Avinger (AVGR), NAYA Biosciences (NAYA), Invivo Therapeutics (NVIVQ), Acutus Medical (AFIB), Dynatronics (DYNT), Bluejay Diagnostics (BJDX), Cutera (CUTR), and Sonendo (SONX). These companies are all part of the "medical equipment" industry.
Sharps Technology vs.
Sharps Technology (NASDAQ:STSS) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, earnings, media sentiment, analyst recommendations, community ranking, institutional ownership, valuation, dividends and profitability.
17.2% of Sharps Technology shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 1.5% of Sharps Technology shares are owned by insiders. Comparatively, 0.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Sharps Technology has a beta of 2.08, suggesting that its share price is 108% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.
ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Sharps Technology, indicating that it is currently the more affordable of the two stocks.
ENDRA Life Sciences received 236 more outperform votes than Sharps Technology when rated by MarketBeat users. However, 100.00% of users gave Sharps Technology an outperform vote while only 62.86% of users gave ENDRA Life Sciences an outperform vote.
ENDRA Life Sciences has a consensus target price of $50.00, indicating a potential upside of 1,156.28%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Sharps Technology.
Sharps Technology's return on equity of -110.40% beat ENDRA Life Sciences' return on equity.
In the previous week, ENDRA Life Sciences had 2 more articles in the media than Sharps Technology. MarketBeat recorded 4 mentions for ENDRA Life Sciences and 2 mentions for Sharps Technology. Sharps Technology's average media sentiment score of 0.94 beat ENDRA Life Sciences' score of 0.22 indicating that Sharps Technology is being referred to more favorably in the media.
Summary
Sharps Technology beats ENDRA Life Sciences on 10 of the 15 factors compared between the two stocks.
Get Sharps Technology News Delivered to You Automatically
Sign up to receive the latest news and ratings for STSS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sharps Technology Competitors List
Related Companies and Tools
This page (NASDAQ:STSS) was last updated on 4/26/2025 by MarketBeat.com Staff
